期刊文献+

载紫杉醇PLGA微球在Skov3卵巢癌荷瘤小鼠体内的治疗效果

Treatment effect of paclitaxel loaded microspheres in Skov3 tumor-bearing nude mice
原文传递
导出
摘要 目的应用乳酸-羟基乙酸共聚物(PLGA)制备载紫杉醇(PTX)PLGA微球,评价PTX-PLGA微球对荷瘤小鼠治疗效果。方法采用4周龄雌性BALB/c-nu裸小鼠建模,将卵巢癌Skov3细胞株注射于裸鼠背部一侧,制备裸小鼠皮下移植瘤。设空白对照组、生理盐水组、PLGA微球悬液组、PTX注射液组和PTX-PLGA微球悬液组。分别对成瘤后荷瘤鼠进行治疗、观察记录、绘制肿瘤生长曲线。对Skov3移植瘤裸小鼠瘤内直接注射药物并应用免疫组化法检测移植瘤微血管密度(MVD)、相关死亡促进因子(Bad)。结果给药6周后,PTX-PLGA微球组瘤内注射抑瘤效果明显大于其他各组(P<0.05),肿瘤体积明显减小,癌细胞增殖受到抑制。结论 PTX-PLGA微球瘤内直接注射对卵巢癌的治疗有明显体内抑瘤效果。 Objective To prepare PLGA [poly (lactic-co-glycolic acid) ] as the sustained-releasing microspheres load- ed with paclitaxel and to evaluate the treatment effect on the implanted tumor induced by Skov3 ceils in the nude mice. Methods Four-week-old female BALB/c-nu mice were used as tumor models by injecting Skov3 cells at the back side, and they were evenly divided into four groups. And inner tumor injection was done by using physiological saline, the PLGA microspheres, the paclitaxel and the paclitaxel loaded PLGA microspheres separately. Then the mice were treated and observed and the tumor growth curves were recorded. Direct inner tumor injection was done and the MVD and Bad was measured by immunohistochemistry. Results After 6 weeks of treatment, tumor size and volume of tumor models treated with PLGA sustained-releasing microspheres loaded with paclitaxel were significantly decreased, compared with those of other groups ( P 〈 0.05 ). Conclusion PLGA sustained-releasing microspheres loaded with pa- clitaxel by direct inner tumor injection has a remarkably inhibitory effect on ovarian cancer.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第1期33-36,共4页 Journal of Shandong University:Health Sciences
基金 山东省科技发展计划(2005GG3202191)
关键词 乳酸-羟基乙酸共聚物 微球 紫杉醇 卵巢肿瘤 Poly lactic-co-glycolic acid Microsphere Paclitaxel Ovarian neoplasms
  • 相关文献

参考文献18

  • 1Vaughn D J, Brown A W Jr, Harker W G, et al. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma[J]. Cancer, 2004, 100(4):746-750.
  • 2Weissleder R. Molecular imaging in cancer[J]. Science, 2006, 312(5777) :1168-1171.
  • 3Markman M. Weekly paclitaxel in the management of ovarian cancer [J]. Semin Oncol, 2000, 27 ( 3Suppl 7 ) : 37-40.
  • 4Shen G, Huang H, Zhang A, et al. In vivo activity of anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian caner xenograft models [J]. Cancer Immunol Immunother, 2011, 60 (3) : 339- 348.
  • 5Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation[J]. Eur J Caner, 2001, 37 (13) : 1590- 1598.
  • 6Orr G A, Verdier-Pinard P, McDaid H, et al. Mechanisms of Taxol resistance related to microtubules [ J ]. Oncongene, 2003, 22 (47) :7280-7295.
  • 7邓联东,孙多先,董岸杰.紫杉醇注射剂的研究[J].药学进展,2002,26(3):152-155. 被引量:24
  • 8Schrader C, Keussen C, Bewig B, et al. Symptoms and signs ofan acute myocardial ischemia caused by chemotherapy with Paclitaxel(Taxol) in a patient with metastatic ovarian carcinoma[J]. Eur J Meal Res, 2005, 10( 11 ): 498-501.
  • 9Kadoyama K, Kuwahara A, Yamamori M, et al. Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS[J]. J Exp Clin Cancer Res, 2011, 30(1): 93.
  • 10Wu C H, Yang C H, Lee J N, et al. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects[J]. Int J Gynecol Cancer, 2001, 11 (4) :295-299.

二级参考文献39

  • 1王辰允,刘燕,曲恒燕,张舜欣,梅兴国.紫杉醇长效缓释微球的制备与评价[J].军事医学科学院院刊,2004,28(6):549-551. 被引量:5
  • 2栾瀚森,王浩,梅蕾,杨莉.减压加热法去除纳曲酮微球中残留二氯甲烷[J].中国医药工业杂志,2005,36(9):545-547. 被引量:2
  • 3余志英,李丽文,杜静,夏俊霞,罗军,骆琦.紫杉醇诱导卵巢癌细胞凋亡及细胞周期改变的研究[J].中国医师杂志,2006,8(3):322-324. 被引量:5
  • 4王美清.紫杉醇的临床毒副作用分析及对策[J].中国热带医学,2007,7(2):237-237. 被引量:7
  • 5[1]Tarr B D, Sambandau T G, Yalkowsky S H. A new parenteral emulsi on for the administration of taxol[J]. Pharm Res, 1987, 4: 162-165.
  • 6[2]Shama A, Mayhew E, Straubinger R M. Antitumor effect of taxol-contai ning liposomes in a taxol-resistant murine tumor model [J]. Cancer Res,19 93, 53: 5877-5881.
  • 7[3]Balasubramanian S V, Straubinger R M. Taxol-lipid interactions: taxo l dependent effects on the physical properties of model membranes [J]. Bioch emistry, 1994, 33: 8941-8947.
  • 8[4]Sharma A, Sharma U S, Straubinger R M. Paclitaxel-liposomes for intr acavitary therapy of intraperitoneal P388 leukemia [J]. Cancer Lett, 1996, 107: 265-272.
  • 9[5]Sharma U S, Balasubramanian S V, Straubinger R M. Pharmaceutical and physical properties of paclitaxel (taxol) complexes with cyclodextrins [J]. J Pharm Sci, 1995, 84: 1223-1230.
  • 10[6]Sharma A, Straubinger R M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes [J]. Pharm Res, 1994,11: 8 89-898.

共引文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部